Biogen Archives

Latest Posts

News and Trends 27 Aug 2015

The 5 things outside Europe you need to know this week (Samsung $1Bn Biotech IPO, Microbiome blindness, Google Biotech)

Hi there! Here are the 5 most important Biotech things that happened outside Europe in the last few days. Enjoy and share! Samsung, Biogen lining up a $1B IPO for biosimilar joint venture: WSJ Samsung is also interested in Biotech and more precisely in Biosimilars. It created a joint-venture with Biogen and now wants to […]

August 27, 2015 - 2 minutesmins - By Philip Hemme

News and Trends 19 Aug 2015

Sobi gets a long-lasting grip on a rare type of Hemophilia

In the 19th century, Queen Victoria passed the Hemophilia B to diverse royal houses of Europe. Today, its characteristic heavy bleedings can be treated quite well, as Swedish Orphan Biovitrum (Sobi) and its partner Biogen showed in the results of an ongoing long-term study. Sobi was formed in 2001 through a fusion of several units […]

August 19, 2015 - 3 minutesmins - By Philip Hemme

News and Trends 8 May 2015

GSK sparks off the Gene Therapy resurgence

GlaxoSmithKline has become the first big pharma company to file a gene therapy approval case to the European Medicines Agency (EMA). The therapy, developed in collaboration with San Raffaele Hospital and the Telethon Foundation in Italy, is designed to cure a disease called adenosine deaminase (ADA) deficiency, which causes severe combined immunodeficiency syndrome, lead to serious infections and, ultimately, death. ADA […]

May 8, 2015 - 4 minutesmins - By Joachim Eeckhout

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us